The trial did not meet the primary endpoint. There was not a statistically significant decrease in total PTSD symptom severity as measured by the Clinician Administered PTSD Scale (CAPS-5) between JZP150 (4mg or 0.3mg) compared to placebo from baseline to week 12. The trial also did not meet the key secondary endpoints of mean change from baseline to week 12 on the Clinical Global Impression of Severity (CGI-S) and the Patient Global Impression of Severity (PGI-S) scales.
'We are deeply grateful to all those who supported and made this trial possible, including the patients who were enrolled, their families, our investigators and trial staff,' said
No new safety signals for JZP150 were observed. The most common treatment emergent adverse events (TEAEs) were headache, nausea and urinary tract infection. These were predominately mild to moderate in severity, and also occurred in placebo-treated participants.
About the JZP150 Phase 2 Trial
The multicenter, double-blind, placebo-controlled randomized, clinical trial (NCT05178316) evaluated two doses (4mg and 0.3mg) of JZP150. The trial randomized 282 adults aged 18 to 70 diagnosed with PTSD using the criteria of the
The primary endpoint of the trial measured participants' changes from baseline to week 12 using the total score from CAPS-5, a structured clinical interview that is considered the gold standard for diagnosing and assessing patients with PTSD. It includes 30 items with which physicians can make PTSD diagnoses and evaluate the severity of the symptoms as well as the impact on social and occupational functioning.2 The trial had several secondary endpoints, including changes in scores on the CGI-S and PGI-S scales from baseline to the end of treatment.
About
Contact:
Email: CorporateAffairsMediaInfo@jazzpharma.com
Tel: +353 1 637 2141
Email: InvestorInfo@jazzpharma.com
Tel: +353 1 634 3211
(C) 2023 Electronic News Publishing, source